Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S6
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.
Roa P et al.
British Journal of Cancer, 2024
Liquid Biopsy Profiling with Multiple Tests in Patients with Metastatic Breast Cancer.
Higa N et al.
Journal of Molecular Pathology, 2024
41614092 (PubMed )
Supplement: NIHMS2059476-supplement-Supplementary_Material.pdf
Utility of Clinical Next Generation Sequencing Tests in KIT/PDGFRA/SDH Wild-Type Gastrointestinal Stromal Tumors.
Denu RA et al.
Cancers, 2024
Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China.
Xu Y et al.
Npj Precision Oncology, 2023
Development of a Cell Line Containing the Chimeric ETV6-NTRK3 Gene. The Search for Mutations of the Tyrosine Kinase Chimeric Domain That Cause Resistance to Larotrectinib.
Boyarskikh UA et al.
Bulletin of Experimental Biology and Medicine, 2023
Progressive metastatic infantile fibrosarcoma with multiple acquired mutations.
Furtado LV et al.
Cold Spring Harbor Molecular Case Studies, 2023
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.
Wang Z et al.
Molecular Biomedicine, 2022
Targeting Gatekeeper Mutations for Kinase Drug Discovery.
Zhou Y et al.
Journal of Medicinal Chemistry, 2022
Kinase Fusion-Related Thyroid Carcinomas: Towards Predictive Models for Advanced Actionable Diagnostics.
Chu YH et al.
Endocrine Pathology, 2022
JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo.
Wang J et al.
Molecules (basel, Switzerland), 2022
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.
Chakravarty D et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2022
Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients.
Nguyen HT et al.
Frontiers in Oncology, 2022
36578946 (PubMed )
Supplement: DataSheet_1.pdf
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.
Somwar R et al.
Communications Biology, 2020
Roles of TrkC Signaling in the Regulation of Tumorigenicity and Metastasis of Cancer.
Jin W
Cancers, 2020
Select a paper to view details